Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.59% | -74.60% | -96.16% | -79.30% | -91.57% |
| Total Depreciation and Amortization | 118.75% | 194.12% | -40.15% | -91.65% | -96.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.63% | -1.27% | 81.82% | -55.09% | -15.20% |
| Change in Net Operating Assets | -1,331.51% | -395.23% | 1,147.96% | 344.63% | -112.31% |
| Cash from Operations | -53.24% | -114.49% | -94.33% | -149.75% | -269.65% |
| Capital Expenditure | 79.86% | 70.90% | 63.78% | -86.15% | -1,007.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 144.94% | 139.09% | -- | -- | -- |
| Cash from Investing | 144.88% | 139.02% | 3,668.50% | -192,750.77% | -1,096,830.77% |
| Total Debt Issued | -- | -- | -93.76% | -93.81% | -93.76% |
| Total Debt Repaid | -- | -- | 90.06% | -- | -- |
| Issuance of Common Stock | 24.11% | 24.11% | -91.00% | -92.49% | 898.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -36.45% | -36.48% | -115.79% | -114.79% | 1,869.50% |
| Cash from Financing | 6.55% | 1.82% | -100.71% | -104.66% | 845.83% |
| Foreign Exchange rate Adjustments | 134.94% | 125.64% | -621.63% | 90.83% | -1,621.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 233.18% | 64.68% | -151.46% | -183.32% | 4,741.14% |